Rajendran Avanthika, Reddy Akshay J, Bisaga Karol, Sommer Dillon A, Prakash Neha, Pokala Vivek T, Yu Zeyu, Bachir Mark, Nawathey Neel, Brahmbhatt Telak, Patel Rakesh
Neuroscience, Reed College, Portland, USA.
Medicine, California University of Science and Medicine, Colton, USA.
Cureus. 2023 Mar 15;15(3):e36211. doi: 10.7759/cureus.36211. eCollection 2023 Mar.
Parkinson's disease (PD) is a prevalent neurodegenerative disorder that occurs in old age due to a decrease in dopamine, which causes nerve cell destruction. This disease is difficult to diagnose since its symptoms are similar to those of the aging process. Those with PD have impaired motor control and function, dyskinesia, and tremors. To treat PD, drugs that enhance the amount of dopamine given to the brain are administered to alleviate symptoms. This inquiry examines the prescription of rotigotine to achieve this objective. The primary objective of this review is to examine the usage of rotigotine in both the late and early stages of PD. The statistical model utilized in the review found that there was not a significant difference in the dosage of rotigotine prescribed to late and early-stage PD patients, however, there were some confounding variables that may have skewed this result; therefore, further research is necessary to validate or nullify this hypothesis.
帕金森病(PD)是一种常见的神经退行性疾病,发生于老年,由于多巴胺减少导致神经细胞破坏。这种疾病难以诊断,因为其症状与衰老过程的症状相似。帕金森病患者存在运动控制和功能受损、运动障碍及震颤。为治疗帕金森病,会使用能增加大脑多巴胺量的药物来缓解症状。本研究探讨罗替戈汀的处方以实现这一目标。本综述的主要目的是研究罗替戈汀在帕金森病晚期和早期的使用情况。综述中使用的统计模型发现,给晚期和早期帕金森病患者开的罗替戈汀剂量没有显著差异,然而,存在一些混杂变量可能使这一结果产生偏差;因此,需要进一步研究来验证或否定这一假设。